Business Wire

AbC-19™ Rapid Test Available for Purchase by Healthcare Professionals

Share

Abingdon Health plc (“the Company”), a leading international developer and manufacturer of high quality and effective rapid tests, announces that the AbC-19™ Rapid Test for the detection of SARS-CoV-2 antibodies is now available for purchase by healthcare professionals on the Abingdon Health website.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005611/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The AbC-19™ Rapid Test Process (Graphic: Business Wire)

The AbC-19™ Rapid Test is a self-contained, highly accurate lateral flow immunoassay designed to give results within 20 minutes at the point of use. The test is designed to confirm the presence of IgG antibodies to the full trimeric spike protein of the SARS-CoV-2 virus. These are the type of antibodies which neutralise the virus and can produce immunity as found after vaccination or following an immune response to COVID-19. The attached image explains the AbC-19™ Rapid Test Process.

Deployed at scale across populations, the test can aid policymakers, healthcare systems, the scientific community, and the public at large by:

  • Assisting health providers, researchers, and governments in understanding the extent of the SARS-CoV-2 infection and its spread through communities (seroprevalence)
  • Enabling researchers to understand whether people are developing immunity
  • Informing the development and evaluation of large-scale vaccine tests, and eventual mass immunisation campaigns.

The AbC-19™ Rapid Test has demonstrated high levels of sensitivity and specificity in a clinical setting. Evaluation studies involving 880 patient samples showed sensitivity of 97.58% (95% confidence level 95.28%-98.95%) and specificity of 99.59% (95% confidence interval 98.53%-99.95%). Further details of this study can be found online at MedRxiv.

The AbC-19™ Rapid Test can be purchased by health professionals on the Abingdon Health website.

Leigh Thomas, SVP Director of Global Sales of Abingdon Health, commented: “Research has underlined the pivotal role of the SARS-CoV-2 Spike protein – and the body’s response to it – in developing immunity to COVID-19. As efforts intensify to build large-scale immunity to the virus, we are confident that the AbC-19™ Rapid Test, an easy-to-use antibody test suitable for use outside of the laboratory by healthcare professionals, will be an invaluable tool in the toolbox in the fight against the virus.”

Please note AbC-19™ Rapid Test is available for professional use only and not for self-testing.

About Abingdon Health plc

Abingdon Health plc is a world leading developer and manufacturer of high-quality rapid tests across all industry sectors, including healthcare and COVID-19. Abingdon is the partner of choice for a growing global customer base and takes projects from initial concept through to routine and large-scale manufacturing and has also developed and marketed its own labelled tests.

The Company offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. This ability has a significant role to play in improving life across the world. To support this aim Abingdon Health has also developed AppDx®, a customisable image capturing technology that transforms a smartphone into a self-sufficient, standalone lateral-flow reader. Founded in 2008, Abingdon Health is headquartered in York, England.

https://www.abingdonhealth.com/

AbC-19TM Rapid Test

The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for COVID-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The same IgG antibodies that are present following infection or vaccination.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Abingdon Health plc
Leigh Thomas, SVP Director of Global Sales of Abingdon Health
+44 (0) 1904 406082
info@abingdonhealth.com

Consilium Strategic Communications
Matthew Neal
Mary-Jane Elliott
Lindsey Neville
+44 (0) 203 709 5700
abingdonhealth@consilium-comms.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Heidrick & Struggles Appoints a New Managing Partner for Their CEO & Board Practice in Europe and Africa2.5.2025 11:27:00 EEST | Press release

Heidrick & Struggles (Nasdaq: HSII), a premier provider of executive search, global leadership advisory and on-demand talent solutions, has appointed Kati Najipoor-Smith as Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa. Based at the Firm’s office in Frankfurt, Germany, Kati brings decades of global executive search and consulting experience to the Heidrick & Struggles team to support boards and CEOs in navigating complex leadership challenges. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501269229/en/ Kati Najipoor-Smith has been appointed Heidrick & Struggles' Regional Co-Managing Partner, CEO & Board Practice, for Europe and Africa Kati began her executive search career at Egon Zehnder in 1999, where she led Global Automotive and later the Global CEO Practice over several years. She advises chairs and CEOs of publicly traded, family-owned, and private-equity-backed companies across sectors

Valeo Foods Group Acquires Freddi Dolciaria S.p.A, Enhancing its Position in the Italian Bakery Sector2.5.2025 11:00:00 EEST | Press release

Valeo Foods Group, one of Europe’s leading producers of quality sweets, treats and snacks, has successfully acquired the Italian sweet bakery producer Freddi Dolciaria S.p.A (“Freddi”), accelerating growth in South-West European region and enhancing its position in the bakery sector. Freddi is an Italian sweet bakery company founded in 1949 by Luigi Freddi and headquartered in Castiglione delle Stiviere, Italy. Specialising in sponge cakes, Freddi has an established presence in both the Italian retail and international markets, with an annual turnover approaching €20 million and 48 employees. This acquisition strengthens Valeo Foods Group’s position in the packaged wafers, cakes, and biscuits category, complementing the existing Balconi business across Southern Europe and international markets. The integration of Freddi is expected to drive sustainable, profitable growth while enhancing production capacity and operational efficiency. It also reinforces Valeo’s continued expansion in th

Perma-Pipe International Holdings, Inc. Announces Fourth Quarter and Fiscal 2024 Financial Results1.5.2025 23:24:00 EEST | Press release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the fourth quarter and 2024 fiscal year ended January 31, 2025. “Sales for the fourth quarter and full year 2024 show moderate growth and were $45.0 million and $158.4 million, resulting in increases of $4.8 million and $7.7 million, compared to the prior year. Income before taxes was $5.3 million and $18.5 million in the fourth quarter and for the full year 2024, which increased by $2.1 million and $8.6 million, compared to the prior year. This significant increase was a result of our focus on higher margin products and services that contributed to improved margin performance. Net income after taxes and minority interest was $1.5 million and $9.0 million in the fourth quarter and for the full year 2024. Although 2024 net income was a decrease of $1.5 million, compared to $10.5 million last year, the reduction was due to a one-time non-cash tax benefit of $5.9 million in the prior year after be

IFF Declares Dividend for Second Quarter 20251.5.2025 23:15:00 EEST | Press release

IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 11, 2025 to shareholders of record as of June 20, 2025. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2025 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20250501776988/en/

Rimini Street Announces Fiscal First Quarter 2025 Financial and Operating Results1.5.2025 23:01:00 EEST | Press release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced results for the fiscal first quarter ended March 31, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250501664008/en/ Select First Quarter 2025 Financial Results Revenue was $104.2 million for the 2025 first quarter, a decrease of 2.4% compared to $106.7 million for the same period last year. U.S. revenue was $50.1 million for the 2025 first quarter, a decrease of 6.9% compared to $53.8 million for the same period last year. International revenue was $54.1 million for the 2025 first quarter, an increase of 2.2% compared to $52.9 million for the same period last year. Subscription revenue was $99.0 million, which accounted for 95.0% of total revenue for the 2025 first quarter, compared to subscription rev

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye